Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-2,27
KB-2,12
PKN64,7664,88-5,48
Msft251,27251,3-1,27
Nokia4,8314,8341,12
IBM148,42148,45-0,46
Mercedes-Benz Group AG64,1664,17-0,02
PFE51,1351,140,14
02.12.2022 17:06:58
Indexy online
AD Index online
select
AD Index online
 

  • 02.12.2022 17:06:41
Emergent Bio (EBS, NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
11,72 -0,76 -0,09 122 109
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 02.12.2022
Popis společnosti
Obecné informace
Název společnostiEmergent Biosolutions Inc
TickerEBS
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
RICEBS
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.12.2021 2 416
Akcie v oběhu k 01.11.2022 49 888 218
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice400 Professional Dr, Suite 400
MěstoGAITHERSBURG
PSČ20879
ZeměUnited States
Kontatní osobaRobert Burrows
Funkce kontaktní osobyVice President, Investor Relations
Telefon12 406 313 200
Fax12406313203
Kontatní telefon12 406 313 280

Business Summary: Emergent BioSolutions, Inc. is a life sciences company focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. It provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. It offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Emergent Biosolutions Inc revenues decreased 26% to $790.2M. Net loss totaled $135.8M vs. income of $41.6M. Revenues reflect Services segment decrease of 57% to $97.2M, Otherr segment decrease of 29% to $27M, Non-U.S Government segment decrease of 25% to $503.5M, U.S.Government segment decrease of 27% to $286.7M. Net loss reflects Other (expense) income.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 02.12.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorRobert Kramer6401.04.201901.01.1999
Chief Financial Officer, Executive Vice President, TreasurerRichard Lindahl5826.03.201826.03.2018
Chief Operating Officer, Executive Vice PresidentAdam Havey5126.07.2021
Executive Vice President - Human Resources and Chief Human Resources OfficerKatherine Strei60
Executive Vice President - External Affairs, General Counsel, Corporate SecretaryJennifer Fox4901.03.202201.03.2022
Executive Vice President - Quality and Ethics and ComplianceColeen Glessner51
Executive Vice President, Chief Strategy and Development OfficerAtul Saran4801.03.2022